186 related articles for article (PubMed ID: 35691175)
1. Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances.
Yu J; Zhang C; Song C
Eur J Med Chem; 2022 Aug; 238():114516. PubMed ID: 35691175
[TBL] [Abstract][Full Text] [Related]
2. Selective Inhibition of the Hsp90α Isoform.
Mishra SJ; Khandelwal A; Banerjee M; Balch M; Peng S; Davis RE; Merfeld T; Munthali V; Deng J; Matts RL; Blagg BSJ
Angew Chem Int Ed Engl; 2021 May; 60(19):10547-10551. PubMed ID: 33621416
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014.
Xiao Y; Liu Y
Curr Drug Targets; 2020; 21(3):302-317. PubMed ID: 31465284
[TBL] [Abstract][Full Text] [Related]
4. Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities.
Dernovšek J; Tomašič T
Pharmacol Ther; 2023 May; 245():108396. PubMed ID: 37001734
[TBL] [Abstract][Full Text] [Related]
5. Pan-HSP90 ligand binding reveals isoform-specific differences in plasticity and water networks.
Stachowski TR; Nithianantham S; Vanarotti M; Lopez K; Fischer M
Protein Sci; 2023 May; 32(5):e4629. PubMed ID: 36938943
[TBL] [Abstract][Full Text] [Related]
6. Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90).
Mak OW; Chand R; Reynisson J; Leung IKH
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31717777
[TBL] [Abstract][Full Text] [Related]
7. Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors.
Bhat R; Tummalapalli SR; Rotella DP
J Med Chem; 2014 Nov; 57(21):8718-28. PubMed ID: 25141341
[TBL] [Abstract][Full Text] [Related]
8. Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor.
Khandelwal A; Kent CN; Balch M; Peng S; Mishra SJ; Deng J; Day VW; Liu W; Subramanian C; Cohen M; Holzbeierlein JM; Matts R; Blagg BSJ
Nat Commun; 2018 Jan; 9(1):425. PubMed ID: 29382832
[TBL] [Abstract][Full Text] [Related]
9. Structure-Based Design, Synthesis, and Biological Evaluation of Hsp90β-Selective Inhibitors.
Chaudhury S; Narasimharao Meka P; Banerjee M; Kent CN; Blagg BSJ
Chemistry; 2021 Oct; 27(59):14747-14764. PubMed ID: 34449940
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous Responses and Isoform Compensation the Dim Therapeutic Window of Hsp90 ATP-Binding Inhibitors in Cancer.
Tang X; Chang C; Mosallaei D; Woodley DT; Schönthal AH; Chen M; Li W
Mol Cell Biol; 2022 Feb; 42(2):e0045921. PubMed ID: 34871064
[TBL] [Abstract][Full Text] [Related]
11. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
Bickel D; Gohlke H
Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
[TBL] [Abstract][Full Text] [Related]
12. Cytosolic Hsp90 Isoform-Specific Functions and Clinical Significance.
Maiti S; Picard D
Biomolecules; 2022 Aug; 12(9):. PubMed ID: 36139005
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
Dutta Gupta S; Bommaka MK; Banerjee A
Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
[TBL] [Abstract][Full Text] [Related]
14. Heat Shock Protein 90 (HSP90) Inhibitors as Anticancer Medicines: A Review on the Computer-Aided Drug Discovery Approaches over the Past Five Years.
Magwenyane AM; Ugbaja SC; Amoako DG; Somboro AM; Khan RB; Kumalo HM
Comput Math Methods Med; 2022; 2022():2147763. PubMed ID: 35685897
[TBL] [Abstract][Full Text] [Related]
15. Recent advances toward the development of Hsp90 C-terminal inhibitors.
Amatya E; Blagg BSJ
Bioorg Med Chem Lett; 2023 Jan; 80():129111. PubMed ID: 36549397
[TBL] [Abstract][Full Text] [Related]
16. The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with
Mishra SJ; Liu W; Beebe K; Banerjee M; Kent CN; Munthali V; Koren J; Taylor JA; Neckers LM; Holzbeierlein J; Blagg BSJ
J Med Chem; 2021 Feb; 64(3):1545-1557. PubMed ID: 33428418
[TBL] [Abstract][Full Text] [Related]
17. Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold.
Mishra SJ; Ghosh S; Stothert AR; Dickey CA; Blagg BS
ACS Chem Biol; 2017 Jan; 12(1):244-253. PubMed ID: 27959508
[TBL] [Abstract][Full Text] [Related]
18. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.
Li Y; Zhang T; Schwartz SJ; Sun D
Drug Resist Updat; 2009; 12(1-2):17-27. PubMed ID: 19179103
[TBL] [Abstract][Full Text] [Related]
19. Recent developments of HSP90 inhibitors: an updated patent review (2020-present).
Liu J; Shu H; Xia Q; You Q; Wang L
Expert Opin Ther Pat; 2024; 34(1-2):1-15. PubMed ID: 38441084
[TBL] [Abstract][Full Text] [Related]
20. The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking.
Peterson LB; Eskew JD; Vielhauer GA; Blagg BS
Mol Pharm; 2012 Jun; 9(6):1841-6. PubMed ID: 22554505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
